about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsCertolizumab pegol (CDP870) for rheumatoid arthritis in adultsTargeting TNF receptors in rheumatoid arthritisReduction of experimental necrotizing enterocolitis with anti-TNF-alphaCurcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-κB activation.Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies.Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel diseaseThe role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease.Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.Dual TNF-α/Cyclin D1 Gene Silencing With an Oral Polymeric Microparticle System as a Novel Strategy for the Treatment of Inflammatory Bowel Disease.Adalimumab (Humira): a brief review for dermatologists.Novel drug delivery strategies for the treatment of inflammatory bowel disease.IgG Fab fragments forming bivalent complexes by a conformational mechanism that is reversible by osmolytes.Mast cell regulation of the immune response.The immune response in inflammatory bowel disease.The role of TNFalpha in ulcerative colitis.Cholinergic modulation of inflammation.Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase.Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapyGlycoprotein CD98 as a receptor for colitis-targeted delivery of nanoparticle.Therapeutic gene delivery using bioreducible polymers.Tumour necrosis factor-alpha-mediated human polymeric immunoglobulin receptor expression is regulated by both mitogen-activated protein kinase and phosphatidylinositol-3-kinase in HT-29 cell line.Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: the role of TLR2 and NOD2.Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-alpha.Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model.Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy.Effects of tripolyphosphate on cellular uptake and RNA interference efficiency of chitosan-based nanoparticles in Raw 264.7 macrophages.Dietary kaempferol suppresses inflammation of dextran sulfate sodium-induced colitis in mice.
P2860
Q24193535-C83D5B27-97A5-4E0D-A0B1-5DBA09653ACCQ24236701-30831F12-75ED-4F13-9080-47E843A825F0Q26853279-F9D1845C-9206-4EF5-BDB7-D4C090022FB9Q28572801-11A2C744-959A-4FCE-A852-537001CC1D84Q33707525-2FD72D45-A911-4D47-960E-83E5B8744D56Q33818370-6AF173C8-9F7E-4CCC-B05D-BFE3CBDCAB04Q34553476-5465613D-DC96-4688-8011-D1D76B91737BQ35814374-FD9833A8-E92E-4D5D-B503-762DB60D31D1Q35999197-1302D10B-05D5-482B-A011-74E8F2A65F50Q36002746-5233C925-76FD-485C-A76F-BC0F43BE5042Q36069543-EDA94127-668F-4A27-A3A7-4C47D1A5EDAAQ36316765-C8C7EA92-7E37-4F2B-901C-9E32ACA9B433Q36466773-E0DE87A6-E007-476D-B5A7-A0C3419C9477Q36834357-6CD095DC-6C84-4169-AFEB-6E391A74030AQ36846736-DD3A5B67-777B-4837-AB10-EFD93D3B13F2Q36849148-2F378EFB-61D4-49DF-8EB3-1E883100DE73Q36992793-5423BDAF-B3F2-446D-AB8C-AFCD0CFCE393Q37139358-E58CD354-A021-497D-BE87-0F7DC590576BQ37146028-06526D55-49AF-4BB9-B77A-84667435E551Q37695146-1FD3E1E3-3DF3-4158-A2B3-0DCC5BCED66EQ38157750-1E509899-7B0D-4E80-BB93-B3077960CC70Q40059939-08A6472D-FA66-486F-BCB2-E073165F4A02Q40120821-DB25D2BA-DA26-4B9D-938A-2AE8853B4997Q40249947-34E9D42B-2F1F-415E-AF07-980C491276DCQ40336783-DF54E180-F715-4222-832D-B50223DA93F4Q43202907-18F5DB76-B9C3-46F6-8635-2434AC786393Q46272530-19139DE6-EF09-4962-A851-8F67098B7D3BQ48020807-81143D93-BA9C-4B58-9B1F-13FF8215F679Q51416714-B101E95F-4AFE-412B-A3A2-82341E984FAF
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Strategies for targeting tumour necrosis factor in IBD.
@ast
Strategies for targeting tumour necrosis factor in IBD.
@en
type
label
Strategies for targeting tumour necrosis factor in IBD.
@ast
Strategies for targeting tumour necrosis factor in IBD.
@en
prefLabel
Strategies for targeting tumour necrosis factor in IBD.
@ast
Strategies for targeting tumour necrosis factor in IBD.
@en
P356
P1476
Strategies for targeting tumour necrosis factor in IBD.
@en
P2093
William J Sandborn
P304
P356
10.1053/BEGA.2002.0345
P577
2003-02-01T00:00:00Z